General Information of Drug (ID: DM1SJZ3)

Drug Name
(S)-Rolipram Drug Info
Synonyms
(S)-(+)-rolipram; 85416-73-5; S-(+)-Rolipram; (S)-ROLIPRAM; S- (+)-Rolipram; UNII-H6G4VMQ24K; H6G4VMQ24K; CHEMBL325795; CHEBI:59540; (4S)-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]PYRROLIDIN-2-ONE; (S)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one; (4S)-4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-pyrrolidin-2-one; S-rolipram; 1oyn; 1xn0; AC1L4KJV; MLS006011228; SCHEMBL5321568; CTK8G3018; DTXSID30234634; HJORMJIFDVBMOB-GFCCVEGCSA-N
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
158758
ChEBI ID
CHEBI:59540
CAS Number
CAS 85416-73-5
TTD Drug ID
DM1SJZ3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [2]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [3]
BI 1015550 DM6DO2P Idiopathic pulmonary fibrosis CB03.4 Phase 3 [4]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [5]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [6]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [7]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [3]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [8]
AWD-12-281 DMVADGZ Rhinitis FA20 Phase 2 [9]
LIRIMILAST DMD4KAU Chronic obstructive pulmonary disease CA22 Phase 2 [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Phosphodiesterase 4 (PDE4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [10]
Oxtriphylline DMLHSE3 Cough MD12 Approved [11]
Roflumilast DMPGHY8 Asthma CA23 Approved [12]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [13]
crisaborole DMNVKU6 Atopic dermatitis EA80 Approved [14]
Arofylline DM84AD1 Chronic obstructive pulmonary disease CA22 Phase 3 [15]
ARQ-151 DML61S4 Atopic dermatitis EA80 Phase 3 [16]
SUN13834 DMPK34E Gram-positive bacterial infection 1B74-1G40 Phase 2 [17]
ONO-6126 DMRT28X Chronic obstructive pulmonary disease CA22 Phase 2 [15]
E6005 DM1S489 Atopic dermatitis EA80 Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dyphylline DM8DZC1 Acute bronchial asthma CA23 Approved [17]
Enprofylline DMFYZKN Asthma CA23 Approved [19]
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [2]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [20]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [21]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [5]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [6]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [7]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [20]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [22]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Inhibitor [1]
Phosphodiesterase 4A (PDE4A) TTZ97H5 PDE4A_HUMAN Inhibitor [1]
Phosphodiesterase 4B (PDE4B) TTVIAT9 PDE4B_HUMAN Inhibitor [1]

References

1 PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69.
2 Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
4 BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol. 2022 Apr 20;13:838449.
5 An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
6 Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
7 Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
8 Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
9 The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
10 Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
13 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
14 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
15 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
16 Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
17 Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
18 Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.
19 Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
21 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
22 GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54.